Literature DB >> 12537629

Evaluation of the patterns of Schistosoma mansoni infection and re-infection in Senegal, from faecal egg counts and serum concentrations of circulating anodic antigen.

K Polman1, F F Stelma, S Le Cessie, S J De Vlas, S T M Falcão Ferreira, I Talla, A M Deelder, B Gryseels.   

Abstract

Infection and re-infection patterns were evaluated in a recent Schistosoma mansoni focus in northern Senegal, by determining concentrations of serum circulating anodic antigen (CAA), as a measure of worm burden, and counting eggs in faeces before, 6 or 12 weeks and 1 year after praziquantel treatment in two subsequent cohorts (cohort A and B). No differences in egg counts and CAA concentrations or their relationship were found between the cohorts, which were examined 2 years apart. Within both cohorts, CAA concentrations showed the same, typical, age-related patterns as egg counts, with a peak in children and a strong decline in adults. These trends were apparent both before and 1 year after treatment. The results indicate that an age-related resistance to infection and to re-infection has been firmly established, at a steady level, in the recent S. mansoni focus investigated, with no indication of a gradual development of immunity or anti-fecundity immunity over a period of 2 years. Both shortly and 1 year after treatment, the decrease in egg counts was stronger than that in CAA concentrations, indicating that that there had been a reduction in worm fecundity after treatment. The possibility that praziquantel may induce anti-fecundity immunity has important implications for the use and interpretation of the results of (egg-count-based) re-infection studies designed to follow the development of naturally acquired immunity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12537629     DOI: 10.1179/000349802125001708

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  7 in total

1.  Previous or ongoing schistosome infections do not compromise the efficacy of the attenuated cercaria vaccine.

Authors:  Thomas M Kariuki; Govert J Van Dam; André M Deelder; Idle O Farah; Dorcas S Yole; R Alan Wilson; Patricia S Coulson
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

2.  Up-converting phosphor technology-based lateral flow assay for detection of Schistosoma circulating anodic antigen in serum.

Authors:  Paul L A M Corstjens; Lisette van Lieshout; Michel Zuiderwijk; Dieuwke Kornelis; Hans J Tanke; Andre M Deelder; Govert J van Dam
Journal:  J Clin Microbiol       Date:  2007-10-17       Impact factor: 5.948

3.  The contribution of water contact behavior to the high Schistosoma mansoni Infection rates observed in the Senegal River Basin.

Authors:  Seydou Sow; Sake J de Vlas; Foekje Stelma; Kim Vereecken; Bruno Gryseels; Katja Polman
Journal:  BMC Infect Dis       Date:  2011-07-18       Impact factor: 3.090

4.  Use of triclabendazole for treatment of patients co-infected by Fasciola spp. and S. mansoni in Behera Governorate, Egypt.

Authors:  Paolo Barduagni; Yehia Hassanein; Mostafa Mohamed; Aly El Wakeel; Mabrouk El Sayed; Zuhair Hallaj; Filippo Curtale
Journal:  Parasitol Res       Date:  2007-12-12       Impact factor: 2.289

5.  Hepatic schistosomiasis.

Authors:  Karin L Andersson; Raymond T Chung
Journal:  Curr Treat Options Gastroenterol       Date:  2007-12

6.  Reconstructing Colonization Dynamics of the Human Parasite Schistosoma mansoni following Anthropogenic Environmental Changes in Northwest Senegal.

Authors:  Frederik Van den Broeck; Gregory E Maes; Maarten H D Larmuseau; David Rollinson; Ibrahima Sy; Djibril Faye; Filip A M Volckaert; Katja Polman; Tine Huyse
Journal:  PLoS Negl Trop Dis       Date:  2015-08-14

7.  Association of Schistosoma mansoni-specific IgG and IgE antibody production and clinical schistosomiasis status in a rural area of Minas Gerais, Brazil.

Authors:  Deborah Negrão-Corrêa; Juliana F Fittipaldi; José Roberto Lambertucci; Mauro Martins Teixeira; Carlos Maurício de Figueiredo Antunes; Mariângela Carneiro
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.